

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

4.5% CONVERTIBLE BONDS DUE 2021 (THE “BONDS”)

(Stock Code: 5320)

FULL CONVERSION AND WITHDRAWAL OF LISTING OF THE BONDS

Reference is made to (i) the announcement of The United Laboratories International Holdings Limited (the “**Company**”) dated 21 November 2016 in relation to the Bonds issued by the Company and (ii) the announcement of the Company dated 17 August 2020 in relation to the proposed redemption of all outstanding Bonds on the Redemption Date. Capitalised terms used herein shall have the same meanings as those defined in the aforesaid announcements unless otherwise stated.

On 31 August 2020, all outstanding Bonds were fully converted into ordinary shares of the Company in accordance with the terms and conditions of the Bonds. Accordingly, there are no outstanding Bonds in issue as at the date of this announcement. The Company has applied to The Stock Exchange of Hong Kong Limited for the withdrawal of the listing of the Bonds. Such withdrawal of listing is expected to become effective upon the close of business on or around 9 September 2020.

On behalf of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 2 September 2020

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.